SCHEMBL3841885

SCHEMBL3841885

[CH2]Cc1cccc([N+](=O)[O-])c1C

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.64
TSHR P16473 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 1/20 0.47
GPR35 Q9HC97 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 2/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
HPGD P15428 2/20 0.43
POLB P06746 1/20 0.42
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14641737 0.85 TDP1 (0.69) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL1067609 0.81 TDP1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL961310 0.81 TSHR (0.67) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL16803358 0.81 TDP1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL14363082 0.81 TDP1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL715298 0.81 TDP1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL10902775 0.81 TDP1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL6205360 0.81 TDP1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL7079985 0.81 TDP1 (0.58) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL34723 0.80 ALDH1A1 (0.64) TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7619095-B2 Process for the preparation of indolone derivative ALEMBIC LIMITED (IN) 2009-11-17 US disclosed
EP-1848691-B1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LTD (IN) 2009-11-11 EP disclosed
US-20080262244-A1 Process for the Preparation of Indolone Derivative ALEMBIC LIMITED (IN) 2008-10-23 US disclosed
EP-1848691-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE Alembic Limited (IN) 2007-10-31 EP disclosed
WO-2006123356-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LIMITED (IN) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262244-A1 Process for the Preparation of Indolone Derivative HTR3C, HTR3B, HTR1B TDP1 1934/4885TSHR 443/4885SMN1; SMN2 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.